» Articles » PMID: 18250304

Gain-of-function Mutation of GATA-2 in Acute Myeloid Transformation of Chronic Myeloid Leukemia

Overview
Specialty Science
Date 2008 Feb 6
PMID 18250304
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

Acquisition of additional genetic and/or epigenetic abnormalities other than the BCR/ABL fusion gene is believed to cause disease progression in chronic myeloid leukemia (CML) from chronic phase to blast crisis (BC). To gain insights into the underlying mechanisms of progression to BC, we screened DNA samples from CML patients during blast transformation for mutations in a number of transcription factor genes that are critical for myeloid-lymphoid development. In 85 cases of CML blast transformation, we identified two new mutations in the coding region of GATA-2, a negative regulator of hematopoietic stem/progenitor cell differentiation. A L359V substitution within zinc finger domain (ZF) 2 of GATA-2 was found in eight cases with myelomonoblastic features, whereas an in-frame deletion of 6 aa (delta341-346) spanning the C-terminal border of ZF1 was detected in one patient at myeloid BC with eosinophilia. Further studies indicated that L359V not only increased transactivation activity of GATA-2 but also enhanced its inhibitory effects on the activity of PU.1, a major regulator of myelopoiesis. Consistent with the myelomonoblastic features of CML transformation with the GATA-2 L359V mutant, transduction of the GATA-2 L359V mutant into HL-60 cells or BCR/ABL-harboring murine cells disturbed myelomonocytic differentiation/proliferation in vitro and in vivo, respectively. These data strongly suggest that GATA-2 mutations may play a role in acute myeloid transformation in a subset of CML patients.

Citing Articles

Modeling GATA2 deficiency in mice: the R396Q mutation disrupts normal hematopoiesis.

Hall T, Mehmood R, Sa da Bandeira D, Cotton A, Klein J, Pruett-Miller S Leukemia. 2025; 39(3):734-747.

PMID: 39774796 PMC: 11879863. DOI: 10.1038/s41375-024-02508-z.


GATA2 deficiency and hemophagocytic lymphohistiocytosis (HLH): a systematic review of reported cases.

Rezaei Zadeh Rukerd M, Mirkamali H, Nakhaie M, Alizadeh S BMC Infect Dis. 2024; 24(1):1239.

PMID: 39497062 PMC: 11536883. DOI: 10.1186/s12879-024-10145-1.


Harnessing the potential of monocytes/macrophages to regenerate tissue-engineered vascular grafts.

Das A, Smith R, Andreadis S Cardiovasc Res. 2024; 120(8):839-854.

PMID: 38742656 PMC: 11218695. DOI: 10.1093/cvr/cvae106.


mutant variant allele frequency may reflect prognosis in Chinese adult patients with de novo cytogenetically normal acute myeloid leukemia.

Ren H, Hong M, Feng J, Hao Z, Chen X, Liang F Biomol Biomed. 2024; 24(4):982-989.

PMID: 38416121 PMC: 11293240. DOI: 10.17305/bb.2024.10244.


Role of the pioneer transcription factor GATA2 in health and disease.

Aktar A, Heit B J Mol Med (Berl). 2023; 101(10):1191-1208.

PMID: 37624387 DOI: 10.1007/s00109-023-02359-8.


References
1.
Parikh C, Subrahmanyam R, Ren R . Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood. 2006; 108(7):2349-57. PMC: 1895567. DOI: 10.1182/blood-2004-08-009498. View

2.
Goga A, McLaughlin J, Afar D, Saffran D, Witte O . Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 1995; 82(6):981-8. DOI: 10.1016/0092-8674(95)90277-5. View

3.
Tong Q, Tsai J, Tan G, Dalgin G, Hotamisligil G . Interaction between GATA and the C/EBP family of transcription factors is critical in GATA-mediated suppression of adipocyte differentiation. Mol Cell Biol. 2005; 25(2):706-15. PMC: 543409. DOI: 10.1128/MCB.25.2.706-715.2005. View

4.
Nieborowska-Skorska M, Stoklosa T, Datta M, Czechowska A, Rink L, Slupianek A . ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks. Cell Cycle. 2006; 5(9):994-1000. DOI: 10.4161/cc.5.9.2722. View

5.
Melo J . The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996; 88(7):2375-84. View